UPDATED INDICATION FOR DUKORAL® TRAVEL VACCINE:
As Canadians Take a Budget-Conscious Approach to Tropical Destinations in 2016,
Enterotoxigenic E. Coli is a Growing Health Risk

KIRKLAND, QC - Monday May 9, 2016 – Valneva Canada Inc. announces that the indication for its DUKORAL® vaccine was recently updated to better describe the appropriate use of this vaccine to prevent diarrhea caused by Enterotoxigenic E. coli (ETEC)

DUKORAL® is an oral vaccine for adults and children aged two and older that is indicated for the prevention of, and protection against, cholera and diarrhea caused by Enterotoxigenic E. coli (ETEC) producing heat-labile enterotoxin (LT), a common medical problem for travellers to tropical or developing countries. Enterotoxigenic E. coli (ETEC) diarrhea is characterized by the sudden onset of loose stools, nausea, vomiting, fever and abdominal cramps that can last for up to five days. While the severity of symptoms can vary, Enterotoxigenic E. coli (ETEC) diarrhea can frequently result in unforeseen medical costs and wasted vacation time.

98% of Travellers Will Make a Food or Beverage Mistake While Abroad

DUKORAL® protects against heat-labile enterotoxin (LT) producing ETEC, a strain of E.coli bacteria that can infect the digestive system via food or water contaminated with human or animal waste, causing outbreaks of diarrhea. Raw fruits and vegetables, raw seafood, undercooked meat or poultry, unpasteurized dairy products, food from street vendors and restaurants and untreated ice and water are all common sources of Enterotoxigenic E. coli (ETEC) contamination. The bacteria is especially prevalent in the Caribbean, Mexico and other Latin American countries, where it has been identified in up to 35% of traveller’s diarrhea cases. Travellers to high-risk regions are often unaware of the risk of ETEC contamination: as many as 98% will make a dietary or beverage mistake within the first three days of their vacation.


A recent survey by Leger shows that Canadians may be at an even higher risk of Enterotoxigenic E. Coli (ETEC) contamination in 2016, as they take a more budget-conscious approach to travel to compensate for the lower Canadian currency.

According to the survey, although as many as 35% of Canadians are still considering travel to the Caribbean or Latin America, the low dollar will motivate many travellers to cut corners in a way that could increase their exposure to Enterotoxigenic E. Coli (ETEC). The survey showed that over half (52%) of Canadians who are considering travel to the Caribbean or Latin America are willing to select a destination country that is more affordable, while at least one-third (33%) are willing to select accommodation options other than all-inclusive resorts. Furthermore, travellers staying in the local community, could drastically increase their chances of contracting Enterotoxigenic E. Coli (ETEC) via contaminated food or water. Canadian travellers should consult a healthcare professional before departure to learn how to stay healthy while travelling abroad.

“Canadians are often unaware of the full breadth of health risks they may face during their travels to either a new or familiar tropical destination,” said Dr. Darin P. Cherniwchan of the Fraser Valley Travel Clinic. “Up to 50% of travellers report being incapacitated for part of the trip due to travellers’ diarrhea. Individuals planning travel to the Caribbean, Mexico or other Latin American countries should be aware that Enterotoxigenic E. coli is one of the most common causes of travellers’ diarrhea in these regions. I encourage travellers to consult a healthcare professional well in advance of their departure date to discuss preventative measures, such as vaccination, as well as appropriate precautions with food selection, water and sanitation while abroad.”
About Dukoral®
Dukoral® is an oral vaccine for adults and children aged two and older that is indicated for the prevention of, and protection against, cholera and Enterotoxigenic E. coli (ETEC)-producing heat-labile enterotoxin (LT) (either LT alone or both LT and heat stable enterotoxin (ST) together). The Enterotoxigenic E. coli (ETEC) bacteria is the most common cause of diarrhea in travellers. Dukoral® causes the body to produce its own protection against cholera and LT-producing ETEC bacteria. After getting the vaccine, the body will produce substances called antibodies, which will fight the cholera and LT-producing ETEC bacteria and toxins that cause diarrhea. Dukoral® is available from a pharmacist without a prescription in all provinces except Quebec, where a doctor’s prescription is required. Protection from ETEC-diarrhea and cholera can be expected about one week after the primary immunization series is completed. A single booster dose of Dukoral® will renew protection against ETEC diarrhea if the last dose was taken in the preceding three months to five years.

Important Safety Information
Dukoral® is intended to help prevent Enterotoxigenic E. coli (ETEC)-diarrhea and/or cholera in adults and children aged two and older. Dukoral® will not prevent diarrhea caused by other organisms. It does not treat cholera or ETEC-diarrhea once it develops. Not everyone who gets vaccinated will be fully protected; therefore, precautions to avoid contaminated food or water should be taken. Side effects may include gastrointestinal upsets, such as abdominal pain, diarrhea, nausea or vomiting, and allergic reactions may occur. Talk to your doctor, nurse or pharmacist if you are not sure whether you should take Dukoral®. Please refer to the Dukoral® Product Monograph for additional safety information and for complete prescribing information, available at www.dukoralcanada.com / www.valneva.ca.

About Valneva Canada
Valneva is a global pure play vaccine company specialized in the development, manufacture and commercialization of innovative vaccines. Valneva’s mission is to protect people from infectious diseases through preventative medicine.

Valneva Canada Inc. is focused on the Canadian marketing and distribution of Valneva’s vaccines, including Dukoral® and Ixiaro®, as well as third-party vaccines. For more information, visit www.valneva.ca

For more information:
Maxime-Elisabeth Illick
NATIONAL Public Relations
(514) 843-2322 / meillick@national.ca

-30-